文献速递急性肾损伤慢性肾脏病

靶向Kim-1的细胞外囊泡:RNAi治疗AKI的新平台

Kim-1 Targeted Extracellular Vesicles: A New Therapeutic Platform for RNAi to Treat AKI.
PubMed 文献 · J Am Soc Nephrol · 2021-06-14

研究利用红细胞来源细胞外囊泡(REVs)装载靶向Kim-1的肽段和siRNA,在小鼠缺血再灌注(I/R)和单侧输尿管梗阻(UUO)模型中递送针对P65和Snai1的siRNA,减轻肾小管间质炎症和纤维化,阻止向CKD转化。

要点

  • Kim-1靶向REVs可高效归巢至损伤肾小管。
  • 双抑制P65和Snai1改善I/R和UUO诱导的肾损伤。
  • 该平台可阻止AKI向CKD转变。

核心结论

  • 靶向Kim-1的红细胞来源细胞外囊泡可递送siRNA至急性损伤肾脏,减轻炎症和纤维化。

研究设计与样本

  • 研究在小鼠肾缺血再灌注(I/R)损伤和单侧输尿管梗阻(UUO)模型中,工程化红细胞来源细胞外囊泡(REVs)以靶向肽和siRNA治疗实验性AKI。

主要发现

  • 经噬菌体展示筛选出结合Kim-1的肽段,RNA测序表征缺血肾脏转录组以探索治疗靶点。
  • 靶向Kim-1的LTH肽修饰REVs(REVLTH)在I/R损伤后高效归巢并聚集于损伤肾小管。
  • 鉴定转录因子P65和Snai1驱动炎症和纤维化,作为潜在治疗靶点。
  • siRNAs靶向P65和Snai1通过REVLTH高效递送至缺血肾脏,阻断肾小管中P-p65和Snai1表达。
  • 双抑制P65和Snai1通过减轻肾小管间质炎症和纤维化,显著改善I/R和UUO诱导的肾损伤,并有效阻止向CKD转变。

临床怎么用

  • 该靶向递送平台可能为AKI提供新的基因治疗策略,但尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: AKI is a significant public health problem with high morbidity and mortality. Unfortunately, no definitive treatment is available for AKI. RNA interference (RNAi) provides a new and potent method for gene therapy to tackle this issue. METHODS: We engineered red blood cell-derived extracellular vesicles (REVs) with targeting peptides and therapeutic siRNAs to treat experimental AKI in a mouse model after renal ischemia/reperfusion (I/R) injury and unilateral ureteral obstruction (UUO). Phage display identified peptides that bind to the kidney injury molecule-1 (Kim-1). RNA-sequencing (RNA-seq) characterized the transcriptome of ischemic kidney to explore potential therapeutic targets. RESULTS: REVs targeted with Kim-1-binding LTH peptide (REVLTH) efficiently homed to and accumulated at the injured tubules in kidney after I/R injury. We identified transcription factors P65 and Snai1 that drive inflammation and fibrosis as potential therapeutic targets. Taking advantage of the established REVLTH, siRNAs targeting P65 and Snai1 were efficiently delivered to ischemic kidney and consequently blocked the expression of P-p65 and Snai1 in tubules. Moreover, dual suppression of P65 and Snai1 significantly improved I/R- and UUO-induced kidney injury by alleviating tubulointerstitial inflammation and fibrosis, and potently abrogated the transition to CKD. CONCLUSIONS: A red blood cell-derived extracellular vesicle platform targeted Kim-1 in acutely injured mouse kidney and delivered siRNAs for transcription factors P65 and Snai1, alleviating inflammation and fibrosis in the tubules.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Tang TT, Wang B, Li ZL, et al. Kim-1 Targeted Extracellular Vesicles: A New Therapeutic Platform for RNAi to Treat AKI. J Am Soc Nephrol. 2021. PMID: 34127536. doi:10.1681/ASN.2020111561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。